Pipeline

Clinical Trials

Click on the title below for current clinical trials information and eligibility criteria.

Topical PTH (1-34)

Phase 2a

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of 0.10% or 0.05% PTH (1-34) Gel versus Placebo Gel in the Treatment of Mild to Moderate Plaque Psoriasis

 

For more information, prospective patients or their physicians should contact Manhattan Pharmaceuticals, Inc. by email at info@manhattanpharma.com.